Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark W Lowdell

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Molecular Therapy. Advances|May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCLClaire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
Blood|July 11, 2025
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionClaire Roddie, Juliana Dias, Maeve O'Reilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Juliana Dias, Maeve A O'Reilly, et al.
Cytotherapy|April 3, 2026
A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancerRebecca N Graham, Alice Davies, Monica L Mullin, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Molecular Therapy. Advances|May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCLClaire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
Blood|July 11, 2025
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionClaire Roddie, Juliana Dias, Maeve O'Reilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Juliana Dias, Maeve A O'Reilly, et al.
Cytotherapy|April 3, 2026
A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancerRebecca N Graham, Alice Davies, Monica L Mullin, et al.
Pageof 8